Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients

INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions occur in ~ 0.3% of all solid tumours but are enriched in some rare tumour types. Tropomyosin receptor kinase (TRK) inhibitors larotrectinib and entrectinib are approved as tumour-agnostic therapies for solid tumours harbouring N...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvertown, Joshua D., Lisle, Connie, Semenuk, Laura, Knapp, Colleen, Jaynes, Jillann, Berg, Doreen, Kaul, Nabodita, Lachapelle, Josianne, Richardson, Leslie, Speevak, Marsha, Sarras, Haya, Berman, David M., Carter, Ronald, Feilotter, Harriet, Feltis, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531629/
https://www.ncbi.nlm.nih.gov/pubmed/36194351
http://dx.doi.org/10.1007/s40291-022-00617-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531629/
https://www.ncbi.nlm.nih.gov/pubmed/36194351
http://dx.doi.org/10.1007/s40291-022-00617-y

Ejemplares similares